Compare AbCellera Biologics Inc (ABCL) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares Core High Dividend ETF — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while iShares Core High Dividend ETF trades at $27.93. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | HDV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $28.09 |
52-Week Low | $2.78 | $23.63 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
HDV trades at $27.70, down 1.21% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF focuses on high-quality, high-dividend U.S. stocks, currently yielding around 3.0%, and has outperformed the S&P 500 over five years with lower volatility. Recent news highlights its defensive sector tilt toward healthcare and energy, though this introduces oil price sensitivity.
The outlook for HDV is favorable for income-focused investors seeking stable dividends and lower market correlation, but risks include sector concentration in energy and competitive pressure from lower-cost dividend ETFs. Long-term performance hinges on sustained dividend growth from its quality-focused portfolio amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
